NCT01061606 · OUTCOME

Overall Survival

Temsirolimus in Treating Patients With Recurrent or Persistent Cancer of the Uterus · Source last updated 2016-11-09

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure: Not reported
Unit: Not reported
Interval / dispersion: Not reported
Time frame: From registration to death, assessed up to 3 years

What was measured

Time to event distributions will be estimated using the Kaplan-Meier method.

Analysis population: The study concluded terminated early and patients were not followed.

Groups in this outcome

Treatment (Temsirolimus)

Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. temsirolimus: Given IV

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

Group	Source count
Treatment (Temsirolimus)	0

Reported measurements

No numerical measurement classes were posted for this outcome. Missing is not zero.

Complete source fields

denoms

counts
group Id
OG000
value
0
units
Participants

description

Time to event distributions will be estimated using the Kaplan-Meier method.

groups

description
Patients receive temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. temsirolimus: Given IV
id
OG000
title
Treatment (Temsirolimus)

population Description

The study concluded terminated early and patients were not followed.

reporting Status

POSTED

time Frame

From registration to death, assessed up to 3 years

title

Overall Survival

type

SECONDARY

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice